Indrayani Biotech Reports Declining Financial Performance Amidst Operational Challenges in August 2025

Indrayani Biotech has recently reported its financial results for the quarter ending June 2025, with the announcement made on August 14, 2025. The company, operating within the Other Agricultural Products industry, has experienced notable challenges in its financial performance during this period.
The evaluation changes indicate a revision in its score, moving from -31 to -17 over the last three months. However, the underlying metrics reveal several areas of concern. The Profit Before Tax (PBT) has shown a significant decline, recorded at Rs -0.85 crore, reflecting a year-on-year decrease of 194.44%. Similarly, the Profit After Tax (PAT) stands at Rs 0.16 crore, down 81.2% year-on-year, suggesting ongoing difficulties in profitability.

Additionally, the inventory turnover ratio has reached its lowest point at 3.15 times, indicating a slowdown in the pace of inventory sales. Net sales have also contracted, reported at Rs 29.10 crore, with a year-on-year decline of 7.71%. The company's reliance on non-operating income, which constitutes 504.76% of PBT, raises concerns about the sustainability of its business model. Furthermore, cash and cash equivalents have dwindled to Rs 0.29 crore, marking a deterioration in short-term liquidity, while the debt-equity ratio has climbed to 1.89 times, suggesting increased borrowing to support operations.

For further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.